Tag Archives: BTCY

Top 5 Low Price Stocks To Invest In Right Now

Sometimes its helpful for investors in small cap mining stocks like Azincourt Energy Corp (TSX-V: AAZ; OTCMKTS: AZURF) to take a look at what other mining stocks operating in the same region and looking for the same minerals are doing or saying in order to have a better understanding of wherethe market is heading.

Denison Mines Corp’s Uranium Commentary

Last Thursday, small cap uranium mining stock Denison Mines Corp (NYSEAMERICAN: DNN), which is also focused on the Athabasca Basin of Saskatchewan, reported 2017 earnings and gave its outlook for 2018 with the outlook coming with extensive commentary about the uranium market and Athabasca. David Cates, the President and CEO of Denison Mines Corp, gave the following commentary:

“2017 was a volatile year for the uranium market. While the spot price of uranium benefited from upward momentum on multiple occasions during the year, that momentum was not sustained long enough for a meaningful change to the low price environment that saw the market reach 12 and 13 year lows in late 2016. Despite these disappointing market trends, Denison managed to have another productive year as we continue to focus on our strategy of positioning the Company for the future and a return to a much higher uranium price.”

Top 5 Low Price Stocks To Invest In Right Now: Templeton Dragon Fund Inc.(TDF)

Advisors’ Opinion:

  • [By Logan Wallace]

    News articles about Templeton Dragon Fund Inc common stock (NYSE:TDF) have trended somewhat positive on Sunday, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Templeton Dragon Fund Inc common stock earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news headlines about the financial services provider an impact score of 45.9946586007156 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

  • [By Shane Hupp]

    Templeton Dragon Fund Inc common stock (NYSE:TDF) major shareholder City Of London Investment Grou bought 8,155 shares of the company’s stock in a transaction that occurred on Tuesday, June 12th. The shares were purchased at an average price of $22.87 per share, with a total value of $186,504.85. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Top 5 Low Price Stocks To Invest In Right Now: Axsome Therapeutics, Inc.(AXSM)

Advisors’ Opinion:

  • [By Paul Ausick]

    Axsome Therapeutics Inc. (NASDAQ: AXSM) traded down about 43% Tuesday and posted a new 52-week low of $3.20 after closing Monday at $5.55. The 52-week high is $6.45. Volume was about 3.8 million, about 19 times the daily average of around 220,000 shares. The company will stop a “futile” portion of a trial of its treatment for knee osteoarthritis.

  • [By Lisa Levin] Gainers
    Comstock Resources, Inc. (NYSE: CRK) shares shot up 52 percent to $7.235 after the company disclosed a deal with Arkoma Drilling L.P. and Williston Drilling, L.P. to buy oil & gas properties in North Dakota. Comstock announced withdrawal of tender offers for outstanding secured notes.
    MarineMax, Inc. (NYSE: HZO) shares gained 24.2 percent to $21.80 as the company posted upbeat Q2 results and raised its FY18 outlook.
    Mattersight Corporation (NASDAQ: MATR) shares rose 22 percent to $2.625 after the company agreed to be purchased by NICE Ltd.
    Chipotle Mexican Grill, Inc. (NYSE: CMG) jumped 21.3 percent to $411.871 as the company reported stronger-than-expected results for its first quarter on Wednesday.
    Axsome Therapeutics, Inc. (NASDAQ: AXSM) rose 17 percent to $3.10 after the company disclosed a positive outcome of the interim analysis of STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression.
    Ultra Clean Holdings, Inc. (NASDAQ: UCTT) rose 15.9 percent to $18.34 following upbeat Q1 earnings.
    PCM, Inc. (NASDAQ: PCMI) gained 15.6 percent to $12.20 following Q1 results.
    O'Reilly Automotive, Inc. (NASDAQ: ORLY) surged 14.4 percent to $260.3901 following upbeat Q1 profit.
    Concord Medical Services Holdings Limited (NYSE: CCM) gained 13.8 percent to $3.70.
    Penn National Gaming, Inc. (NASDAQ: PENN) rose 13.5 percent to $29.815 after reporting strong Q1 results.
    BioTelemetry, Inc. (NASDAQ: BEAT) rose 13.5 percent to $38.30 as the company reported stronger-than-expected earnings for its first quarter.
    Advanced Micro Devices, Inc. (NASDAQ: AMD) shares rose 13.1 percent to $10.985 as the company reported upbeat results for its first quarter.
    SJW Group (NYSE: SJW) shares gained 11.8 percent to $63.59 following Q1 results. California Water Service Group made an offer for SJW.
    Churchill Downs Incorporated (NASDAQ: CHDN) climbed 9.8 percent to $278.40 following Q1 results.
    CYS Investments, Inc. (NYSE: CYS)
  • [By Chris Lange]

    Axsome Therapeutics Inc. (NASDAQ: AXSM) is evaluating AXS-05 in its Stride-1 Phase 3 trial in treatment-resistant depression. Top-line results are expected by the end of March. Axsome previously received an FDA Fast Track designation for AXS-05.

  • [By Max Byerly]

    Axsome Therapeutics (NASDAQ:AXSM) released its quarterly earnings results on Tuesday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.09, Bloomberg Earnings reports.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Axsome Therapeutics (AXSM)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Low Price Stocks To Invest In Right Now: Cumberland Pharmaceuticals Inc.(CPIX)

Advisors’ Opinion:

  • [By Logan Wallace]

    JW Asset Management LLC cut its stake in Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) by 32.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 178,942 shares of the specialty pharmaceutical company’s stock after selling 84,939 shares during the period. Cumberland Pharmaceuticals comprises about 1.2% of JW Asset Management LLC’s holdings, making the stock its 16th largest holding. JW Asset Management LLC owned about 1.14% of Cumberland Pharmaceuticals worth $1,195,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Max Byerly]

    COPYRIGHT VIOLATION NOTICE: “Cumberland Pharmaceuticals (CPIX) Research Coverage Started at B. Riley” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at www.tickerreport.com/banking-finance/3364464/cumberland-pharmaceuticals-cpix-research-coverage-started-at-b-riley.html.

Top 5 Low Price Stocks To Invest In Right Now: Coca-Cola Enterprises, Inc.(CCE)

Advisors’ Opinion:

  • [By Logan Wallace]

    Clinton Group Inc. acquired a new position in shares of Coca-Cola European Partners PLC (NYSE:CCE) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 128,976 shares of the company’s stock, valued at approximately $5,242,000. Coca-Cola European Partners comprises 0.8% of Clinton Group Inc.’s investment portfolio, making the stock its 20th largest holding.

  • [By Shane Hupp]

    Coca-Cola European Partners (NYSE:CCE) announced its quarterly earnings results on Thursday. The company reported $0.67 earnings per share for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.11), Bloomberg Earnings reports. Coca-Cola European Partners had a return on equity of 15.52% and a net margin of 5.70%. The company had revenue of $3.06 billion during the quarter, compared to analyst estimates of $3.07 billion. During the same period in the prior year, the firm earned $0.67 EPS. Coca-Cola European Partners’s quarterly revenue was up .1% on a year-over-year basis. Coca-Cola European Partners updated its FY18 guidance to EUR2.25-2.27 EPS.

  • [By Stephan Byrd]

    These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

    Get Coca-Cola European Partners alerts:

    Coca-Cola European Partners (CCE) Lowered to “Sell” at ValuEngine (americanbankingnews.com) $3.69 Billion in Sales Expected for Coca-Cola European Partners (CCE) This Quarter (americanbankingnews.com) Zacks: Analysts Anticipate Coca-Cola European Partners (CCE) to Post $0.81 EPS (americanbankingnews.com) Critical Contrast: Coca-Cola European Partners (CCE) and Coca-Cola Bottling Co. Consolidated (COKE) (americanbankingnews.com) Coca-Cola European Partners (CCE) Sees Large Drop in Short Interest (americanbankingnews.com)

    Shares of CCE traded down $0.51 during trading hours on Monday, hitting $37.88. The stock had a trading volume of 705,278 shares, compared to its average volume of 1,496,087. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.03 and a quick ratio of 0.79. The company has a market cap of $18.60 billion, a PE ratio of 15.85, a P/E/G ratio of 1.93 and a beta of 0.76. Coca-Cola European Partners has a 1-year low of $36.17 and a 1-year high of $44.75.

  • [By ]

    Analysts upgraded Coca-Cola European Partners PLC  (CCE) to buy on its commitment to deleveraging and capital allocation.

    Goldman still rates Monster Beverage Corp. (MNST) as a buy given the global expansion of the energy drink category.

  • [By Joseph Griffin]

    Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of Coca-Cola European Partners PLC (NYSE:CCE) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 31,000 shares of the company’s stock, valued at approximately $1,260,000.

Top 5 Low Price Stocks To Invest In Right Now: Biotricity (BTCY)

Advisors’ Opinion:

  • [By Peter Graham]

    For small cap investors, Biotricity Inc (OTCQB: BTCY) is a good example of an up-and-coming Internet of Medical Things stock that is looking to cash in on the coming transformation of health care. The Company is building a remote patient monitoring platform comprised of three key components tailored to a variety of diagnostic and post-diagnostic applications:

  • [By Peter Graham]

    Small cap Internet of Medical Things (IoMT) company Biotricity, Inc (OTCBB: BTCY) has just announced that it will be expanding the scope of a previously approved clinical investigation of fetal heart rate variability (fHRV) to include maternal HRV and other key physiologic metrics for maximum predictive accuracy and efficiency. This is potentially a good area to be in due to the fact that high-risk pregnancies require extensive monitoring and care during the gestational period. High-risk pregnancies are also on the rise and now account for 6 – 8% of all pregnancies in the U.S. due in part to a rise in existing maternal health conditions (such as high blood pressure and obesity) and older parental age at the time of pregnancy. This means that the maternal and fetal monitoring market is growing rapidly and is expected to be worth $2.3 Billion by 2019. 

  • [By Peter Graham]

    According to a recent report (“Internet of Medical Things Enabling Hospitals of the Future”) from Frost & Sullivan, the Internet of Medical Things (IoMT) is helping to drive the home healthcare industry into new innovations that are clustered around wearables and eSkin devices – the type of devices that small cap Biotricity Inc (OTCQB: BTCY) is developing. To begin with, the Internet of Medical Things is part of the much bigger Internet of Things (IoT) idea with IoMT consisting connected medical devices or applications feeding medical or patient data into the cloud via online networks. In addition and aside from Internet of Medical Things, there is also another trend in healthcare to move away from “reactive” healthcare where a patient visits a healthcare facility to deal with a problem and to instead move toward “proactive” healthcare care where the patient takes a degree of responsibility for their own health through the use of health monitoring systems (enabled by IoMT). 

Top 5 Value Stocks To Buy Right Now

There are dozens of large-cap value exchange-traded funds for value investors to consider. One of the most venerable is the Vanguard Value ETF (NYSE: VTV).

VTV, which tracks the CRSP US Large Cap Value Index, is beloved among value investors for several reasons, not the least of which is its low fee. The Vanguard fund charges just 0.05 percent per year, the equivalent of $5 on a $10,000 investment. That makes VTV less expensive than 95 percent of competing value strategies, according to issuer data.

What Happened

On a historical basis, value stocks often outperform their growth and momentum counterparts with less volatility over long holdings periods. However, during the course of the current bull market in U.S. stocks, the value factor is lagging growth and momentum.

Over the past three years, VTV is trailing its growth counterpart, the Vanguard Growth ETF (NYSE: VUG), by nearly 1,000 basis points. During the same period, VTV has delivered barely more than half the returns of the growth-oriented Nasdaq-100 Index.

Why It's Important

“Large-value stocks tend to be mature businesses that are often trading at low valuations for good reason, including slow expected growth and, in some cases, high business risk,” said Morningstar in a note on VTV last Friday.

Top 5 Value Stocks To Buy Right Now: Staffing 360 Solutions, Inc.(STAF)

Advisors’ Opinion:

  • [By Shane Hupp]

    Staffing 360 Solutions (NASDAQ: STAF) and ADECCO Grp AG/ADR (OTCMKTS:AHEXY) are both business services companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Staffing 360 Solutions (STAF)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Alexander Bird]

    Here are the top performers from last week…

    Penny Stock Current Share Price Last Week’s Gain
    Staffing 360 Solutions Inc. (Nasdaq: STAF) $2.58 96.35%
    IZEA Inc. (Nasdaq: IZEA) $1.65 85.19%
    ShiftPixy Inc. (Nasdaq: PIXY) $3.35 78.38%
    MER Telemanagement Solutions Ltd. (Nasdaq: MTSL) $3.31 41.07%
    IsoRay Inc. (NYSE: ISR) $0.60 38.64%
    TransGlobe Energy Corp. (Nasdaq: TGA) $3.74 37.76%
    Actinium Pharmaceuticals Inc. (OTCMKTS: ATNM) $0.27 26.31%
    Blonder Tongue Labs Inc. (NYSE: BDR) $1.56 24.58%
    Bridgeline Digital Inc. (Nasdaq: BLIN) $1.51 24.51%
    Cel-Sci Corp. (NYSE: CVM) $0.91 24.03%

    While these penny stocks generated strong returns last week, they’re unlikely to produce the same level of profit again anytime soon.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Staffing 360 Solutions (STAF)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Value Stocks To Buy Right Now: Biotricity (BTCY)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap Internet of Medical Things (IoMT) company Biotricity, Inc (OTCBB: BTCY) has just announced that it will be expanding the scope of a previously approved clinical investigation of fetal heart rate variability (fHRV) to include maternal HRV and other key physiologic metrics for maximum predictive accuracy and efficiency. This is potentially a good area to be in due to the fact that high-risk pregnancies require extensive monitoring and care during the gestational period. High-risk pregnancies are also on the rise and now account for 6 – 8% of all pregnancies in the U.S. due in part to a rise in existing maternal health conditions (such as high blood pressure and obesity) and older parental age at the time of pregnancy. This means that the maternal and fetal monitoring market is growing rapidly and is expected to be worth $2.3 Billion by 2019. 

  • [By Peter Graham]

    On Tuesday, small cap Internet of Medical Things (IoMT) stock Biotricity Inc (OTCQB: BTCY) announced the expansion of its sales team to cover two additional geographic centers in the US that are key to driving faster adoption of its flagship Bioflux product – the first application of a platform where the Company has tailored Internet of Things (IoT) hardware, Real Time Operating System (RTOS) and the cloud for the diagnostic cardiac market.

  • [By Jim Robertson]

    MedicalResearch.com recently interviewed Waqaas Al-Siddiq, the Founder and CEO of small cap Internet of Medical Things (IoMT) company Biotricity Inc (OTCQB: BTCY), about the future of medical wearables and their interaction with deep data and artificial intelligence (AI). Biotricity itself is specialized in remote monitoring solutions for chronic illnesses who’s platform is comprised of three key components tailored to a variety of diagnostic and post-diagnostic applications:  

  • [By Peter Graham]

    According to a recent report (“Internet of Medical Things Enabling Hospitals of the Future”) from Frost & Sullivan, the Internet of Medical Things (IoMT) is helping to drive the home healthcare industry into new innovations that are clustered around wearables and eSkin devices – the type of devices that small cap Biotricity Inc (OTCQB: BTCY) is developing. To begin with, the Internet of Medical Things is part of the much bigger Internet of Things (IoT) idea with IoMT consisting connected medical devices or applications feeding medical or patient data into the cloud via online networks. In addition and aside from Internet of Medical Things, there is also another trend in healthcare to move away from “reactive” healthcare where a patient visits a healthcare facility to deal with a problem and to instead move toward “proactive” healthcare care where the patient takes a degree of responsibility for their own health through the use of health monitoring systems (enabled by IoMT). 

  • [By Peter Graham]

    Up-and-coming small cap Internet of Medical Things (IoMT) company Biotricity, Inc (OTCBB: BTCY) announced this week that it is developing “Biopatch” – an ECG patch building on the Company’s flagship Bioflux product. Biotricity itself is building a remote patient monitoring platform comprised of three key components:

  • [By Jim Robertson]

    Earlier this month, the Apple Watch Series 4 having a heart monitoring function approved by the FDA generated a large amount of attention from the media; but is that heart monitoring function all that its cracked out to be and what does it mean for other heart monitoring makers like small cap Biotricity Inc (OTCQB: BTCY)? Note that the Series 4 includes two new FDA-cleared features: An over-the-counter ECG app that monitors heart rhythms and an “irregular rhythm notification feature” that “analyzes pulse rate data to identify episodes of irregular heart rhythms suggestive of atrial fibrillation (AFib).” However, HealthNewsReview.org has a post (What did journalists overlook about the Apple Watch ‘heart monitor’ feature?) reviewing some of the media coverage and was somewhat critical of all the hype. The post noted:

Top 5 Value Stocks To Buy Right Now: Solar Senior Capital Ltd.(SUNS)

Advisors’ Opinion:

  • [By Logan Wallace]

    Maxim Group reaffirmed their buy rating on shares of Solar Senior Capital (NASDAQ:SUNS) in a research report released on Tuesday. They currently have a $18.50 target price on the asset manager’s stock.

  • [By Logan Wallace]

    These are some of the headlines that may have impacted Accern’s scoring:

    Get Solar Senior Capital alerts:

    Financial Survey: Solar Capital (SLRC) vs. Solar Senior Capital (SUNS) (americanbankingnews.com) Research Analysts Offer Predictions for Solar Senior Capital Ltd’s Q1 2019 Earnings (SUNS) (americanbankingnews.com) Solar Capital Ltd (SLRC) CEO Michael Gross on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com) Solar Senior Capital’s (SUNS) Buy Rating Reiterated at Maxim Group (americanbankingnews.com) Solar Senior Capital NII in-line, misses on revenue (seekingalpha.com)

    SUNS stock traded down $0.07 during trading on Monday, hitting $16.85. The company had a trading volume of 7,787 shares, compared to its average volume of 28,851. The company has a market capitalization of $271.40 million, a PE ratio of 11.95 and a beta of 0.60. Solar Senior Capital has a 52-week low of $16.10 and a 52-week high of $18.40.

  • [By Joseph Griffin]

    Hercules Technology Growth Capital (NYSE: HTGC) and Solar Senior Capital (NASDAQ:SUNS) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

  • [By Max Byerly]

    Solar Senior Capital Ltd (NASDAQ:SUNS) announced a monthly dividend on Thursday, June 7th, Wall Street Journal reports. Investors of record on Thursday, June 21st will be paid a dividend of 0.1175 per share by the asset manager on Tuesday, July 3rd. This represents a $1.41 dividend on an annualized basis and a yield of 8.46%. The ex-dividend date of this dividend is Wednesday, June 20th. This is a boost from Solar Senior Capital’s previous monthly dividend of $0.12.

Top 5 Value Stocks To Buy Right Now: Del Taco Restaurants, Inc.(TACO)

Advisors’ Opinion:

  • [By Max Byerly]

    The analysts wrote, “We maintain our Buy rating and $19 price target on Del Taco (TACO) as the company’s 3Q18 (September) draws to a close. We lower our 3Q18 (September) EPS estimate to $0.15, from $0.16, though maintain our above-guidance $0.63 EPS estimate for 2018. Our EPS estimates of $0.72 for 2019 (vs. $0.67 consensus) and $0.79 for 2020 are unchanged. We believe recent M&A activity in the industry will push TACO’s valuation multiples higher.””

  • [By Stephan Byrd]

    Arcos Dorados (NYSE:ARCO) and Del Taco Restaurants (NASDAQ:TACO) are both small-cap retail/wholesale companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

  • [By Dan Caplinger]

    The stock market largely gained ground on Friday, although triple-digit gains for the Dow Jones Industrial Average were offset somewhat by modest losses in the Nasdaq Composite. European Union tariffs were set to take effect today on more than $3 billion in U.S. goods, representing the latest escalation in trade tensions between the U.S. and trade partners across the globe. Yet investors were ready for a break after several days of poor performance for the overall market, and good news from several companies helped set a positive mood on Wall Street. Marathon Oil (NYSE:MRO), WillScot (NASDAQ: WSC), and Del Taco Restaurants (NASDAQ:TACO) were among the best performers on the day. Here’s why they did so well.

Top 5 Value Stocks To Buy Right Now: Compania Cervecerias Unidas, S.A.(CCU)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Beverage stocks have been a hit-or-miss proposition in the U.S., both for megabrewers and for smaller players in the craft beer, spirits, and soft drink industries. But there are plenty of opportunities internationally to invest in the companies that produce drinks. In Chile, Compania Cervecerias Unidas (NYSE:CCU) produces beer, wine, and soft drinks for several South American countries, and after having seen a slow period to finish 2017, CCU had hoped to find ways to bounce back to start the new year.

  • [By Max Byerly]

    News coverage about Compania Cervecerias Unidas, S.A. Common Stock (NYSE:CCU) has trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Compania Cervecerias Unidas, S.A. Common Stock earned a news sentiment score of 0.06 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.6257635339829 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

  • [By Joseph Griffin]

    Stevens Capital Management LP increased its holdings in shares of Compania Cervecerias Unidas, S.A. Common Stock (NYSE:CCU) by 53.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,154 shares of the company’s stock after purchasing an additional 6,292 shares during the period. Stevens Capital Management LP’s holdings in Compania Cervecerias Unidas, S.A. Common Stock were worth $453,000 as of its most recent SEC filing.

Top 10 Stocks To Buy For 2019

Intersect Capital LLC trimmed its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 2.7% in the 2nd quarter, HoldingsChannel reports. The firm owned 51,680 shares of the company’s stock after selling 1,439 shares during the period. Merck & Co., Inc. makes up 1.5% of Intersect Capital LLC’s investment portfolio, making the stock its 15th biggest position. Intersect Capital LLC’s holdings in Merck & Co., Inc. were worth $3,137,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Clearwater Capital Advisors LLC acquired a new position in shares of Merck & Co., Inc. during the 1st quarter worth about $103,000. SRS Capital Advisors Inc. boosted its position in shares of Merck & Co., Inc. by 208.4% during the 1st quarter. SRS Capital Advisors Inc. now owns 1,983 shares of the company’s stock worth $108,000 after acquiring an additional 1,340 shares in the last quarter. Taylor Wealth Management Partners acquired a new position in shares of Merck & Co., Inc. during the 2nd quarter worth about $110,000. Creative Financial Designs Inc. ADV boosted its position in shares of Merck & Co., Inc. by 155.2% during the 2nd quarter. Creative Financial Designs Inc. ADV now owns 1,832 shares of the company’s stock worth $111,000 after acquiring an additional 1,114 shares in the last quarter. Finally, Well Done LLC acquired a new position in shares of Merck & Co., Inc. during the 1st quarter worth about $115,000. 72.20% of the stock is owned by hedge funds and other institutional investors.

Top 10 Stocks To Buy For 2019: Koppers Holdings Inc.(KOP)

Advisors’ Opinion:

  • [By Logan Wallace]

    Mackay Shields LLC reduced its holdings in shares of Koppers Holdings Inc. (NYSE:KOP) by 61.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 22,786 shares of the specialty chemicals company’s stock after selling 36,800 shares during the period. Mackay Shields LLC owned about 0.11% of Koppers worth $874,000 at the end of the most recent reporting period.

  • [By Stephan Byrd]

    Koppers (NYSE:KOP) was upgraded by equities research analysts at TheStreet from a “c” rating to a “b-” rating in a report released on Friday.

  • [By Logan Wallace]

    Koppers (NYSE:KOP) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Top 10 Stocks To Buy For 2019: BancFirst Corporation(BANF)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Community Bank System (NYSE: CBU) and BancFirst (NASDAQ:BANF) are both finance companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.

  • [By Joseph Griffin]

    BidaskClub upgraded shares of BancFirst (NASDAQ:BANF) from a buy rating to a strong-buy rating in a research report sent to investors on Thursday.

    BANF has been the subject of several other reports. Zacks Investment Research upgraded shares of BancFirst from a hold rating to a buy rating and set a $65.00 target price for the company in a research report on Monday, April 23rd. ValuEngine upgraded shares of BancFirst from a sell rating to a hold rating in a research report on Wednesday, May 2nd. Finally, Keefe, Bruyette & Woods restated a hold rating and set a $60.00 target price on shares of BancFirst in a research report on Friday, April 20th.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on BancFirst (BANF)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Get a free copy of the Zacks research report on BancFirst (BANF)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on BancFirst (BANF)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Stocks To Buy For 2019: Golden Entertainment, Inc.(GDEN)

Advisors’ Opinion:

  • [By Logan Wallace]

    Shares of Golden Entertainment Inc (NASDAQ:GDEN) have received a consensus rating of “Hold” from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $36.67.

  • [By Max Byerly]

    Press coverage about Golden Entertainment (NASDAQ:GDEN) has trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Golden Entertainment earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.4533629478547 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

  • [By Shane Hupp]

    News coverage about Golden Entertainment (NASDAQ:GDEN) has been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Golden Entertainment earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.5212527362401 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

  • [By Logan Wallace]

    Golden Entertainment Inc (NASDAQ:GDEN) shares traded up 7.2% during mid-day trading on Tuesday . The company traded as high as $25.31 and last traded at $25.29. 501,759 shares traded hands during mid-day trading, an increase of 47% from the average session volume of 341,759 shares. The stock had previously closed at $23.59.

Top 10 Stocks To Buy For 2019: Ellie Mae, Inc.(ELLI)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Shares of Ellie Mae Inc (NYSE:ELLI) have earned a consensus rating of “Hold” from the seventeen ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $108.54.

  • [By Dan Caplinger]

    Investors are scared about the state of the mortgage market, and that’s created consternation about mortgage software platform provider Ellie Mae (NYSE:ELLI) and its ability to keep producing the huge growth that it has seen in recent years. Concerns about rising interest rates have been around for a year now, but only recently have rate increases from the Federal Reserve on the short-term end of the yield curve actually started to have a substantial upward impact on longer-term fixed mortgage rates.

  • [By Max Byerly]

    Shares of Ellie Mae Inc (NYSE:ELLI) have been given an average recommendation of “Hold” by the eighteen analysts that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $108.54.

Top 10 Stocks To Buy For 2019: Wellesley Bancorp, Inc.(WEBK)

Advisors’ Opinion:

  • [By Logan Wallace]

    Wellesley Bancorp Inc (NASDAQ:WEBK) CEO Thomas J. Fontaine sold 1,000 shares of the firm’s stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $33.26, for a total transaction of $33,260.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

  • [By Stephan Byrd]

    Media stories about Wellesley Bancorp (NASDAQ:WEBK) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Wellesley Bancorp earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave headlines about the bank an impact score of 46.9511251966149 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

  • [By Logan Wallace]

    News articles about Wellesley Bancorp (NASDAQ:WEBK) have trended somewhat positive on Tuesday, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Wellesley Bancorp earned a daily sentiment score of 0.02 on Accern’s scale. Accern also gave news coverage about the bank an impact score of 46.4011157327553 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

  • [By Logan Wallace]

    Wellesley Bancorp Inc (NASDAQ:WEBK) announced a quarterly dividend on Thursday, August 23rd, Wall Street Journal reports. Investors of record on Wednesday, September 5th will be paid a dividend of 0.055 per share by the bank on Wednesday, September 19th. This represents a $0.22 annualized dividend and a yield of 0.65%. The ex-dividend date is Tuesday, September 4th.

Top 10 Stocks To Buy For 2019: Biotricity (BTCY)

Advisors’ Opinion:

  • [By Peter Graham]

    According to a recent report (“Internet of Medical Things Enabling Hospitals of the Future”) from Frost & Sullivan, the Internet of Medical Things (IoMT) is helping to drive the home healthcare industry into new innovations that are clustered around wearables and eSkin devices – the type of devices that small cap Biotricity Inc (OTCQB: BTCY) is developing. To begin with, the Internet of Medical Things is part of the much bigger Internet of Things (IoT) idea with IoMT consisting connected medical devices or applications feeding medical or patient data into the cloud via online networks. In addition and aside from Internet of Medical Things, there is also another trend in healthcare to move away from “reactive” healthcare where a patient visits a healthcare facility to deal with a problem and to instead move toward “proactive” healthcare care where the patient takes a degree of responsibility for their own health through the use of health monitoring systems (enabled by IoMT). 

  • [By Jim Robertson]

    MedicalResearch.com recently interviewed Waqaas Al-Siddiq, the Founder and CEO of small cap Internet of Medical Things (IoMT) company Biotricity Inc (OTCQB: BTCY), about the future of medical wearables and their interaction with deep data and artificial intelligence (AI). Biotricity itself is specialized in remote monitoring solutions for chronic illnesses who’s platform is comprised of three key components tailored to a variety of diagnostic and post-diagnostic applications:  

  • [By Peter Graham]

    On Tuesday, small cap Internet of Medical Things (IoMT) stock Biotricity Inc (OTCQB: BTCY) announced the expansion of its sales team to cover two additional geographic centers in the US that are key to driving faster adoption of its flagship Bioflux product – the first application of a platform where the Company has tailored Internet of Things (IoT) hardware, Real Time Operating System (RTOS) and the cloud for the diagnostic cardiac market.

  • [By Peter Graham]

    Small cap Internet of Medical Things (IoMT) company Biotricity Inc (OTCQB: BTCY), which is building a remote patient monitoring platform, has just released operational updates for fiscal Q2 2018 (which ended September 30, 2018). To begin with, Bioflux 1.0 (which is a high-precision, single-unit mobile cardiac telemetry or MCT device that provides real-time monitoring and transmission of ambulatory patients’ ECG information) experienced record high sales growth and market expansion during the fiscal Q2 2018 – including a 150% increase in total device sales and a 75% increase in new customers from Q1. Existing customers continued to purchase additional units leading to a 62% increase in repeat customer orders from Q1.

  • [By Peter Graham]

    Small cap Internet of Medical Things (IoMT) company Biotricity, Inc (OTCBB: BTCY) has just announced that it will be expanding the scope of a previously approved clinical investigation of fetal heart rate variability (fHRV) to include maternal HRV and other key physiologic metrics for maximum predictive accuracy and efficiency. This is potentially a good area to be in due to the fact that high-risk pregnancies require extensive monitoring and care during the gestational period. High-risk pregnancies are also on the rise and now account for 6 – 8% of all pregnancies in the U.S. due in part to a rise in existing maternal health conditions (such as high blood pressure and obesity) and older parental age at the time of pregnancy. This means that the maternal and fetal monitoring market is growing rapidly and is expected to be worth $2.3 Billion by 2019. 

Top 10 Stocks To Buy For 2019: Investment Technology Group, Inc.(ITG)

Advisors’ Opinion:

  • [By Max Byerly]

    SEI Investments (NASDAQ: SEIC) and Investment Technology Group (NYSE:ITG) are both finance companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

  • [By Joseph Griffin]

    Investment Technology Group (NYSE:ITG) announced a quarterly dividend on Thursday, May 17th, RTT News reports. Investors of record on Wednesday, May 30th will be given a dividend of 0.07 per share by the financial services provider on Friday, June 15th. This represents a $0.28 dividend on an annualized basis and a yield of 1.23%.

Top 10 Stocks To Buy For 2019: Semgroup Corporation(SEMG)

Advisors’ Opinion:

  • [By Logan Wallace]

    Barclays PLC grew its holdings in SemGroup Corp (NYSE:SEMG) by 32.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 20,779 shares of the pipeline company’s stock after purchasing an additional 5,090 shares during the period. Barclays PLC’s holdings in SemGroup were worth $444,000 as of its most recent SEC filing.

  • [By Joseph Griffin]

    SemGroup (NYSE:SEMG) was downgraded by analysts at ValuEngine from a hold rating to a sell rating.

    Signet Jewelers (NYSE:SIG) was downgraded by analysts at ValuEngine from a hold rating to a sell rating.

  • [By Logan Wallace]

    News headlines about SemGroup (NYSE:SEMG) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. SemGroup earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the pipeline company an impact score of 45.1707332632932 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

  • [By Logan Wallace]

    Shares of SemGroup Corp (NYSE:SEMG) have been given a consensus rating of “Hold” by the fourteen analysts that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $27.63.

  • [By Shane Hupp]

    SemGroup (NYSE: SEMG) and Halliburton (NYSE:HAL) are both oils/energy companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

  • [By Max Byerly]

    NCS Multistage (NASDAQ:NCSM) and SemGroup (NYSE:SEMG) are both small-cap oils/energy companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Top 10 Stocks To Buy For 2019: Argan, Inc.(AGX)

Advisors’ Opinion:

  • [By Max Byerly]

    Federated Investors Inc. PA raised its position in Argan, Inc. (NYSE:AGX) by 26.6% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 99,678 shares of the construction company’s stock after buying an additional 20,936 shares during the period. Federated Investors Inc. PA’s holdings in Argan were worth $4,282,000 as of its most recent filing with the SEC.

  • [By Joseph Griffin]

    State Board of Administration of Florida Retirement System decreased its holdings in Argan, Inc. (NYSE:AGX) by 26.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,343 shares of the construction company’s stock after selling 1,907 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Argan were worth $229,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    Media stories about Argan (NYSE:AGX) have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Argan earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned news stories about the construction company an impact score of 45.7492523122329 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Top 10 Stocks To Buy For 2019: AdvanSix Inc. (ASIX)

Advisors’ Opinion:

  • [By Joseph Griffin]

    AdvanSix Inc (NYSE:ASIX) shares hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $32.23 and last traded at $32.33, with a volume of 2848 shares trading hands. The stock had previously closed at $32.70.

  • [By Max Byerly]

    AdvanSix (NYSE:ASIX) Director Michael Marberry bought 1,398 shares of the stock in a transaction on Monday, May 7th. The stock was purchased at an average price of $35.74 per share, for a total transaction of $49,964.52. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

  • [By Ethan Ryder]

    GSA Capital Partners LLP reduced its holdings in AdvanSix Inc (NYSE:ASIX) by 36.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,620 shares of the company’s stock after selling 14,277 shares during the quarter. GSA Capital Partners LLP owned about 0.08% of AdvanSix worth $856,000 as of its most recent filing with the SEC.

Best Low Price Stocks To Buy Right Now

Growth versus value investing is one of the major debates in the investment world.  Growth stocks seem to have outperformed their value counterparts over the past few years. But the winning streak of growth investing took a hit this year with value stocks regaining lost glory.

It is currently speculated that value investing will likely continue its winning run in the upcoming years. Hence, adding potential stocks to one’s portfolio might prove to be an ideal option in the current scenario.

Value vs. Growth Investing: Long-Drawn Debate

Value investors seek to invest in stocks that are believed to be trading at a discounted value. Investors look for favorable value ratios including low price-to-earnings (P/E) and price-to-book value (P/B) ratios to identify potential value stocks. While a significant number of these stocks are also expected to come with solid dividend payments, these stocks are also expected to moderate growth prospects.

Best Low Price Stocks To Buy Right Now: Coherent, Inc.(COHR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Rofin-Sinar Technologies (NASDAQ: RSTI) got a boost, shooting up 37 percent to $31.50 as Coherent, Inc. (NASDAQ: COHR) announced its plans to buy Rofin-Sinar Technologies Inc in a deal valued at around $942 million.

Best Low Price Stocks To Buy Right Now: Biotricity (BTCY)

Advisors’ Opinion:

  • [By Matthew Briar]

    Biotricity Inc (OTCMKTS:BTCY) announced on Tuesday morning it was teaming up with Global to Local (G2L) to develop remote monitoring solutions that not only work, but serve the underserved (medically speaking) community. This partnership is of particular interest to current and would-be BTCY investors, as it will likely validate the crux of the work the company has done thus far.

    Biotricity is the developer of two different though related technologies. One is called bioflux, and the other is called biolife. Both are heart-monitoring devices… the former for use by caregivers in a clinical setting, while the latter is for use by individuals outside of a clinical setting. Neither is on the market yet, but both are projected to be on the market next year. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device.

    The technology is unique, in that it not only provides stunningly accurate detailed information about a patient’s heart function, but it constantly feeds that data – remotely – to a caregiver and monitor that can make good use of that data. In August the company announced AT&T Inc. (NYSE:T) would be handling the wireless (cellular) connectivity between clinics and patients’ bioflux devices.

    It’s a breakthrough, for many reasons, not the least of which is that remote monitoring lowers overall healthcare costs for those patients, and ultimately, for insurers.

    The hardware is not yet available on a commercial basis, but it is being tested in a clinical setting. The Global to Local partnership will be another field test of sorts, validating the work Biotricity has performed on the R&D front.

    The organization says

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Robert J. Smith]

    Biotricity (OTCBB: BTCY) is a comer in the rapidly growing medical device market and is a small cap to take notice of. Driving this lucrative market are; IoT-driven device connectivity, governmental pressure to cut healthcare costs, escalating hospital costs, a need to reduce hospital readmission rates, an aging population, and a high rate of people with chronic disease. The largest factor driving this market is the rapidly growing rate of those afflicted with chronic disease.

  • [By James E. Brumley]

    Biotricity Inc (OTCMKTS:BTCY), a developer of remote health-monitoring devices, reminded us not so gently today that while it’s waiting on the last of the necessary approvals from the FDA for its hardware, it’s still moving the ball downfield (so to speak). That is to say, it’s already lined up a manufacturer for its so-called Bioflux cardiac monitor for when the last green light is given, and it’s a good one…. Providence Enterprise . That’s the same company that makes some of the equipment and goods within your sight right now.

    Biotricity is the name behind two pieces of technology, both of which are nearing the end of their development. One is the aforementioned Bioflux, and the other is called biolife…. the latter for use by individuals outside of a clinical setting. Neither is on the market yet, but both are projected to be on the market this year. In fact, the company demonstrated its IoT-connected bioflux at this year’s Mobile World Congress (MWC) 2017 in Barcelona, Spain a couple of weeks ago. The crowd liked what it saw.

    The marketable version of the device isn’t available yet; it’s still going through the approval process. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device, and that portion of the review takes longer.

    Still, the company is rightfully optimistic, so much so that it’s already lined up a company to manufacture the Bioflux device once the final approval and final specs are in. That company is Providence Enterprise, which has a long history in making drug delivery and diagnostic equipment, as well as plenty of experience making electronics. The Bioflux will be a blend of both capabilities.

    It’s in

Best Low Price Stocks To Buy Right Now: Juniper Pharmaceuticals, Inc.(JNP)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Monday, our Under the Radar Moversnewsletter suggested shorting women’s health stock Juniper Pharmaceuticals (NASDAQ: JNP):

    Juniper Pharmaceuticals shares have yet to break under a key support level at $5.00. But, waiting until that happens may be too late. After some continued testing of that floor, if-and-when the support should break, the ensuing selloff could materialize in a hurry. If you’re not it at the time it happens, you may not be able to get in at a decent price.

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewsletter suggested shorting small cap women’s health therapeutic stock Juniper Pharmaceuticals (NASDAQ: JNP):

Top 10 Value Stocks For 2018

Investment company PhiloSmith Capital Corp buys Validus Holdings, Black Knight Inc, sells Chubb, Arch Capital Group, First American Financial Corp, Hiscox during the 3-months ended 2017-12-31, according to the most recent filings of the investment company, PhiloSmith Capital Corp. As of 2017-12-31, PhiloSmith Capital Corp owns 30 stocks with a total value of $115 million. These are the details of the buys and sells.

New Purchases: BKI, Added Positions: VR, JRVR, Reduced Positions: PRI, RJF, BRO, AEL, RGA, RLI, Sold Out: CB, ACGL, FAF, HCXLF,

For the details of PhiloSmith Capital Corp’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=PhiloSmith+Capital+Corp

These are the top 5 holdings of PhiloSmith Capital CorpPrimerica Inc (PRI) – 106,700 shares, 9.44% of the total portfolio. Shares reduced by 13.04%Reinsurance Group of America Inc (RGA) – 60,550 shares, 8.23% of the total portfolio. Shares reduced by 7.63%Brown & Brown Inc (BRO) – 178,225 shares, 7.99% of the total portfolio. Shares reduced by 7.76%Arthur J. Gallagher & Co (AJG) – 143,725 shares, 7.93% of the total portfolio. Mentor Graphics Corp (MENT) – 47,700 shares, 7.04% of the total portfolio. Shares reduced by 17.33%New Purchase: Black Knight Inc (BKI)

PhiloSmith Capital Corp initiated holdings in Black Knight Inc. The purchase prices were between $42 and $46.85, with an estimated average price of $45.2. The stock is now traded at around $46.70. The impact to the portfolio due to this purchase was 1.3%. The holdings were 33,881 shares as of 2017-12-31.

Top 10 Value Stocks For 2018: Brunswick Corporation(BC)

Advisors’ Opinion:

  • [By Stephan Byrd]

    ILLEGAL ACTIVITY WARNING: “$1.15 Billion in Sales Expected for Brunswick Co. (BC) This Quarter” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at www.tickerreport.com/banking-finance/3380347/1-15-billion-in-sales-expected-for-brunswick-co-bc-this-quarter.html.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Brunswick (BC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Value Stocks For 2018: New Media Investment Group Inc.(NEWM)

Advisors’ Opinion:

  • [By Joseph Griffin]

    New Media Inv Group (NYSE: NEWM) and News (NASDAQ:NWS) are both consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.

Top 10 Value Stocks For 2018: Biotricity (BTCY)

Advisors’ Opinion:

  • [By Robert J. Smith]

    Biotricity (OTCBB: BTCY) is a comer in the rapidly growing medical device market and is a small cap to take notice of. Driving this lucrative market are; IoT-driven device connectivity, governmental pressure to cut healthcare costs, escalating hospital costs, a need to reduce hospital readmission rates, an aging population, and a high rate of people with chronic disease. The largest factor driving this market is the rapidly growing rate of those afflicted with chronic disease.

  • [By James E. Brumley]

    Biotricity Inc (OTCMKTS:BTCY), a developer of remote health-monitoring devices, reminded us not so gently today that while it’s waiting on the last of the necessary approvals from the FDA for its hardware, it’s still moving the ball downfield (so to speak). That is to say, it’s already lined up a manufacturer for its so-called Bioflux cardiac monitor for when the last green light is given, and it’s a good one…. Providence Enterprise . That’s the same company that makes some of the equipment and goods within your sight right now.

    Biotricity is the name behind two pieces of technology, both of which are nearing the end of their development. One is the aforementioned Bioflux, and the other is called biolife…. the latter for use by individuals outside of a clinical setting. Neither is on the market yet, but both are projected to be on the market this year. In fact, the company demonstrated its IoT-connected bioflux at this year’s Mobile World Congress (MWC) 2017 in Barcelona, Spain a couple of weeks ago. The crowd liked what it saw.

    The marketable version of the device isn’t available yet; it’s still going through the approval process. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device, and that portion of the review takes longer.

    Still, the company is rightfully optimistic, so much so that it’s already lined up a company to manufacture the Bioflux device once the final approval and final specs are in. That company is Providence Enterprise, which has a long history in making drug delivery and diagnostic equipment, as well as plenty of experience making electronics. The Bioflux will be a blend of both capabilities.

    It’s in

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Bryan Murphy]

    As much progress as the remote medical monitoring device market has made in recent years, we’ve still only scratched the surface. The surface has been scratched though. The Dexcom G5 mobile glucose monitor from DexCom, Inc. (NASDAQ:DXCM) is one impressive example. Arguably the first and best entry in the race, DexCom has sent a clear message that consumers and caregivers are ready for a functional device that takes care of itself.

    At the other end of the spectrum is a recent round of products that are less clinical in nature, and more broad-usage friendly. Devices like the Apple Inc. (NASDAQ:AAPL) watch and the Fitbit Inc (NYSE:FIT) line of products are both capable of monitoring heart rates and activity. On the other, neither does it all that well… not like one would expect in a clinical setting. Fitbit has run into a headwind of legal and reputational trouble since it’s been verified that its trackers aren’t all that accurate; Apple avoided such trouble largely because few consumers ever viewed its watches as medical-grade hardware.

    The gap between the Dexcom G5 and the Fitbit fitness trackers, however, is where real opportunity lies. See, the entries to date have proven there is a market for mobile medical devices , but have also proven they have to work as well as the equipment one might expect to find in a doctor’s office or in a hospital.

    It’s this subtle nuance that puts a young company called Biotricity Inc. (OTCMKTS:BTCY) in the spotlight, as it has melded mobile monitoring and quality monitoring, and is now in the midst of making sure they’re marketable… not just to consumers, but to insurance companies (which tend to pay a lot more than the average consumer does). Fitbit missed the mark on both fronts.

    Biotricity is working two different but similar pieces of technology. One is called bioflux, for use by caregivers in a clinical setting, and the other is biolife individuals outside of a clinical setting. Neither is o

Top 10 Value Stocks For 2018: CobalTech Mining Inc. (BNCIF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The other junior cobalt miners include Brixton Metals Corporation (OTC:BXTMD) [TSXV:BBB], Canadian International Minerals [TSXV:CIN], Clean TeQ (OTCPK:CTEQF) [ASX:CLQ], Cobalt Power Group (TSXV:CPO), CobalTech Mining [TSXV:CSK] (OTCPK:BNCIF), Conico Ltd (ASX:CNJ), Corazon Mining Ltd [ASX:CZN], Dragon Energy (ASX:DLE), Highlands Pacific (OTC:HLPCF), Hinterland Metals Inc (TSXV:HMI) (OTC:HNLMF), and LiCo Energy Metals (TSXV:LIC) (OTCQB:WCTXF).

Top 10 Value Stocks For 2018: T2 Biosystems, Inc.(TTOO)

Advisors’ Opinion:

  • [By William Romov]

    Penny Stocks to Buy for December 2017, No. 5: T2 Biosystems Inc. (Nasdaq: TTOO)

    Currently trading at $4.10 per share, T2 Biosystems Inc. (Nasdaq: TTOO) makes diagnostic products for biological in vitro research. It has the highest share price of the penny stocks on our list today.

  • [By Lisa Levin]

    Shares of T2 Biosystems Inc (NASDAQ: TTOO) were down 29 percent to $5.41. T2 Biosystems extended timeline for the completion of the T2Bacteria trial. BTIG downgraded the rating on T2 Biosystems from Buy to Sell, while lowering the price target from $12 to $4.

  • [By Lisa Levin]

    T2 Biosystems Inc (NASDAQ: TTOO) shares were also up, gaining 15 percent to $7.48 after the company disclosed a $40 million equity investment by partner Canon U.S.A.

Top 10 Value Stocks For 2018: Masco Corporation(MAS)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    United Technologies Corporation (NYSE: UTX) is estimated to report quarterly earnings at $1.51 per share on revenue of $14.62 billion.
    The Coca-Cola Company (NYSE: KO) is expected to report quarterly earnings at $0.46 per share on revenue of $7.31 billion.
    Caterpillar Inc. (NYSE: CAT) is projected to report quarterly earnings at $2.07 per share on revenue of $11.93 billion.
    Verizon Communications Inc. (NYSE: VZ) is expected to report quarterly earnings at $1.11 per share on revenue of $31.22 billion.
    Lockheed Martin Corporation (NYSE: LMT) is estimated to report quarterly earnings at $3.42 per share on revenue of $11.28 billion.
    The Sherwin-Williams Company (NYSE: SHW) is projected to report quarterly earnings at $3.15 per share on revenue of $3.94 billion.
    Biogen Inc. (NASDAQ: BIIB) is expected to report quarterly earnings at $5.92 per share on revenue of $3.15 billion.
    3M Company (NYSE: MMM) is estimated to report quarterly earnings at $2.52 per share on revenue of $8.26 billion.
    JetBlue Airways Corporation (NASDAQ: JBLU) is projected to report quarterly earnings at $0.2 per share on revenue of $1.75 billion.
    Eli Lilly and Company (NYSE: LLY) is expected to report quarterly earnings at $1.13 per share on revenue of $5.49 billion.
    Harley-Davidson, Inc. (NYSE: HOG) is estimated to report quarterly earnings at $0.88 per share on revenue of $1.25 billion.
    Corning Incorporated (NYSE: GLW) is expected to report quarterly earnings at $0.3 per share on revenue of $2.50 billion.
    Centene Corporation (NYSE: CNC) is projected to report quarterly earnings at $1.88 per share on revenue of $13.28 billion.
    The Travelers Companies, Inc. (NYSE: TRV) is estimated to report quarterly earnings at $2.77 per share on revenue of $6.75 billion.
    Wipro Limited (NYSE: WIT) is expected to report quarterly earnings at $0.07 per share on revenue of $2.16 billion.
    PACCAR Inc (NASDAQ: PCAR) is projected to
  • [By ]

    Masco (MAS) : “I like Masco. We have a housing shortage and that’s good for Masco.”

    Over on Real Money, Cramer says the Netflix  (NFLX) numbers show that cord-cutting is more than palpable. Get more of his insights with a free trial subscription to Real Money.

  • [By WWW.THESTREET.COM]

    Now, while Home Depot (HD) didn’t take off on these figures, Whirlpool (WHR) jumped more than four points. My take? Home Depot becomes a stock to put on your radar screen as we bounce around Dow 20,000. I am partial to Masco (MAS) , the kitchen and bath company, too, off these numbers.

  • [By WWW.THESTREET.COM]

    When companies break up, they can create enormous value, and nowhere is that more evident than with TopBuild (BLD) , the former services arm of Masco (MAS) that began trading as an independent company in July 2015. Since the spinoff, shares of TopBuild have rallied 50% and Cramer said the move is not yet over.

Top 10 Value Stocks For 2018: Seres Therapeutics, Inc.(MCRB)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
  • [By Lisa Levin]

    Seres Therapeutics Inc (NASDAQ: MCRB) shares dropped 70 percent to $10.69 after the company reported interim results from SER-109 Phase 2 ECOSPOR study in multiply recurrent clostridium difficile infection. The study did not achieve primary endpoint.

  • [By Lisa Levin]

    Seres Therapeutics Inc (NASDAQ: MCRB) shares shot up 35 percent to $12.51. Seres Therapeutics reported initiation of new SER-019 study announced FY16 loss of $2.30 per share on revenue of $21.766 million.

Top 10 Value Stocks For 2018: BioDelivery Sciences International Inc.(BDSI)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Tuesday, healthcare shares fell 0.48 percent. Meanwhile, top losers in the sector included MannKind Corporation (NASDAQ: MNKD), down 10 percent, and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) down 10 percent.

  • [By Jim Robertson]

    On Friday, our Elite Opportunity Pronewsletter suggested small cap specialty pharmaceuticalstock BioDelivery Sciences International (NASDAQ: BDSI) as a bullish/long trade:

Top 10 Value Stocks For 2018: Taiwan Semiconductor Manufacturing Company Ltd.(TSM)

Advisors’ Opinion:

  • [By Ashraf Eassa]

    For many years, NVIDIA (NASDAQ:NVDA) has relied on Taiwan Semiconductor Manufacturing Company (NYSE:TSM) to manufacture the graphics chips it designs. Today, most of NVIDIA’s Pascal architecture-based graphics processors — from the GeForce GTX 1060, designed for mainstream PC gamers, all the way through its cutting edge Tesla P100 datacenter accelerators — are manufactured by TSMC.

  • [By Garrett Baldwin]

    Shares of Apple Inc. (Nasdaq: AAPL) may face additional pressure today after another surprise update from one of its biggest suppliers. Austria-based supplier AMS, a maker of optical sensors for the iPhone X, warned that sales for the second quarter will fall by roughly 50% from the first quarter. This comes not long after Taiwan Semiconductor Manufacturing Co. Ltd.(ADR) (NYSE: TSM) offered a lower-than-expected Q2 revenue forecast. Now, Wall Street analysts could soon follow with cuts to iPhone sales forecasts, especially after rival Samsung warned of a slowdown in display panel sales.
    This morning, the European Central Bank announced it will maintain its record-low interest rates and accommodating monetary policy. At a time when the U.S. central bank is raising rates, the ECB failed to provide a timeline on when it will end its massive stimulus package, which features monthly bond purchases of $37 billion.
    Four Stocks to Watch Today: DNKN, QSR, GM, FB
    Hedge fund manager and notable short-seller Jim Chanos is lining up positions against two of the restaurant industry’s best-known firms. Shares of Dunkin Brands Group Inc.(Nasdaq: DNKN) and Restaurant Brands International Inc. (NYSE: QSR), which owns Burger King, were both sliding after Chanos said he was short the firms over sales concerns. The news comes the same morning that DNKN topped Wall Street profit estimates of $0.62 by $0.11. However, DNKN quarterly revenue fell short of expectations.
    Facebook Inc. (Nasdaq: FB) stock doesn’t appear to be facing any significant fallout due to its ongoing data scandal. The social media giant shattered revenue expectations after the bell Wednesday. Shares popped 7% after the company reported a 50% year-over-year revenue surge. The firm reported 1.45 billion daily active users and 2.2 billion monthly users. This was the first earnings report since the Cambridge Analytica scandal that happened in March. Shares are rebounding, as the firm had lost billions in

  • [By ]

    Though it was hardly a secret going into April that iPhone X sales have come under pressure following a strong start, chip giant Taiwan Semiconductor’s (TSM) guidance and earnings call commentary suggests the slump is even more pronounced than many previously believed.

  • [By Ashraf Eassa]

    Contract chip manufacturing giantTaiwan Semiconductor Manufacturing Company(NYSE:TSM) announced that it expects its revenue for the entirety of 2018 to grow by “about 10%” — a downward revision from its previous forecast of between 10% and 15% revenue growth.

Top 10 Value Stocks For 2018: DRDGOLD Limited(DRD)

Advisors’ Opinion:

  • [By Alex McGuire]

    This list ranks gold dividend stocks in the mining sector by dividend yield. And it also includes one of our top gold stock recommendations of 2017…

    Gold Dividend Stock Share Price Year-to-Date Performance Dividend Yield (as of June 30)
    DRDGOLD Ltd. (NYSE ADR: DRD) $3.19 -39.7% 10.24%
    Sibanye Gold Ltd. (NYSE ADR: SBGL) $4.70 -33.4% 5.98%
    Harmony Gold Mining Co. (NYSE ADR: HMY) $1.62 -26.7% 4.56%
    Gold Fields Limited (NYSE ADR: GFI) $3.41 +13.3% 2.73%
    Randgold Resources Ltd. (Nasdaq ADR: GOLD) $87.68 +14.9% 1.89%
    Franco Nevada Corp. (NYSE: FNV) $72.39 +21.1% 1.27%
    Royal Gold Inc. (Nasdaq: RGLD) $76.85 +21.3% 1.25%
    Eldorado Gold Corp. (NYSE: EGO) $2.58 -19.9% 1.16%
    Barrick Gold Corp. (NYSE: ABX) $15.90 -0.5% 0.75%
    Goldcorp Inc. (NYSE: GG) $13.02 -4.4% 0.62%

    Six of the 10 gold stocks listed above have posted negative returns so far in 2017. The main reason behind their losses has to do with gold price volatility.

  • [By Lisa Levin]

    In trading on Wednesday, basic materials shares fell by 1.27 percent. Meanwhile, top losers in the sector included McEwen Mining Inc (NYSE: MUX), down 12 percent, and DRDGOLD Ltd. (ADR) (NYSE: DRD), down 7 percent.

  • [By Lisa Levin]

    Tuesday afternoon, the basic materials sector proved to be a source of strength for the market. Leading the sector was strength from Endeavour Silver Corp (NYSE: EXK) and DRDGOLD Ltd. (ADR) (NYSE: DRD).

Hot Performing Stocks To Invest In Right Now

March 20, 2017: Markets opened slightly lower Monday and traded close to the break-even line all day. Leading indicators and consumer sentiment readings were both strong. Only the materials sector traded high late in the afternoon while energy and utilities were the laggards. The blue chips were performing best. WTI crude oil for April delivery settled at $48.22 a barrel, down 1.2% on the day. April gold added 0.3% on the day to settle at $1,234.00. Equities were headed for a mixed close shortly before the bell as the DJIA traded up 0.03% for the day, the S&P 500 traded down 0.14%, and the Nasdaq Composite traded up 0.02%.

Stocks traded very near the break-even line just minutes before the closing bell. The closing tally could finish with either a small gain or a small loss for any or all of the indexes.

The DJIA stock posting the largest daily percentage gain ahead of the close Monday was Caterpillar Inc. (NYSE: CAT) which traded up 2.66% at $95.38. The stock’s 52-week range is $69.04 to $99.46. Volume was roughly 15% below the daily average of around 5 million shares. The company reported a 1% decline in February retail sales this morning, the best year-over-year mark in more than 4 years.

Hot Performing Stocks To Invest In Right Now: Daktronics, Inc.(DAKT)

Advisors’ Opinion:

  • [By Monica Gerson]

    Daktronics, Inc. (NASDAQ: DAKT) is estimated to report its quarterly earnings at $0.08 per share on revenue of $156.17 million. Daktronics shares slipped 0.13 percent to close at $7.97 on Tuesday.

  • [By Monica Gerson]

    Daktronics, Inc. (NASDAQ: DAKT) is projected to report its quarterly earnings at $0.08 per share on revenue of $156.17 million.

    Guidewire Software Inc (NYSE: GWRE) is estimated to post its quarterly earnings at $0.06 per share on revenue of $92.43 million.

Hot Performing Stocks To Invest In Right Now: Deltic Timber Corporation(DEL)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11

Hot Performing Stocks To Invest In Right Now: Cubic Corporation(CUB)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    In actuality, we think the reverse is true for several reasons. We believe that there is a higher level of investor neglect in the small cap space, and neglect, in an investment sense, creates valuation discounts from fair value. Small cap names are less well-known and understood. For example, most of you have never heard of Cubic Corporation (NYSE:CUB), but you have likely used the public transportation systems in New York, London, Sydney, etc. that rely on Cubic for fare collection services. Likewise, Multi-Color is a confusing name for the second largest label maker in the world. To understand these businesses, investors need to dig a little deeper with active fundamental research – a Third Avenue strength.

  • [By Lisa Levin]

    Cubic Corporation (NYSE: CUB) shares were also up, gaining 15 percent to $61.45. Cubic reported Q4 net income of $13.2 million, after posting a loss in the year-ago period. Cubic also disclosed that it has been selected for contract from Boston MBTA to deliver next-generation fare payment system.

  • [By Jim Robertson]

    On Friday, small cap Cubic Corporation (NYSE: CUB) had closed up 10.26% with shares rising again in early Monday trading. Cubic Corporation designs, integrates and operates systems, products and services focused in the transportation, defense training and secure communications markets. As the parent company of two major business units,the Companysmission is to increase situational awareness and understanding for customers worldwide. Cubic Transportation Systems is a leading integrator of payment and information technology and services to create intelligent travel solutions for public transit authorities and operators whileCubic Global Defense is a leading provider of realistic combat training systems, secure communications and networking and highly specialized support services for military and security forces of the U.S. and allied nations.

Hot Performing Stocks To Invest In Right Now: NovoCure Limited(NVCR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Novocure Ltd (NASDAQ: NVCR) shares shot up 22 percent to $7.27 after the company posted a narrower-than-expected Q3 loss.

    Shares of TriNet Group Inc (NYSE: TNET) got a boost, shooting up 15 percent to $20.43. TriNet reported Q3 earnings of $0.29 per share on revenue of $770.5 million.

  • [By Chris Lange]

    NocoCure Ltd. (NASDAQ: NVCR) is scheduled to release its fourth-quarter earnings report on February 22 as well. The consensus estimates call for a net loss of $0.11 per share and $53.52 million in revenue. The same period of last year had a net loss of $0.26 per share and $30.24 million in revenue. Shares of Novocure most recently closed at $21.50, with a consensus price target of $27.00 and a 52-week range of $6.75 to $24.15.

Hot Performing Stocks To Invest In Right Now: Biotricity (BTCY)

Advisors’ Opinion:

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By James E. Brumley]

    Biotricity Inc (OTCMKTS:BTCY), a developer of remote health-monitoring devices, reminded us not so gently today that while it’s waiting on the last of the necessary approvals from the FDA for its hardware, it’s still moving the ball downfield (so to speak). That is to say, it’s already lined up a manufacturer for its so-called Bioflux cardiac monitor for when the last green light is given, and it’s a good one…. Providence Enterprise . That’s the same company that makes some of the equipment and goods within your sight right now.

    Biotricity is the name behind two pieces of technology, both of which are nearing the end of their development. One is the aforementioned Bioflux, and the other is called biolife…. the latter for use by individuals outside of a clinical setting. Neither is on the market yet, but both are projected to be on the market this year. In fact, the company demonstrated its IoT-connected bioflux at this year’s Mobile World Congress (MWC) 2017 in Barcelona, Spain a couple of weeks ago. The crowd liked what it saw.

    The marketable version of the device isn’t available yet; it’s still going through the approval process. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device, and that portion of the review takes longer.

    Still, the company is rightfully optimistic, so much so that it’s already lined up a company to manufacture the Bioflux device once the final approval and final specs are in. That company is Providence Enterprise, which has a long history in making drug delivery and diagnostic equipment, as well as plenty of experience making electronics. The Bioflux will be a blend of both capabilities.

    It’s in

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Robert J. Smith]

    Biotricity (OTCBB: BTCY) is a comer in the rapidly growing medical device market and is a small cap to take notice of. Driving this lucrative market are; IoT-driven device connectivity, governmental pressure to cut healthcare costs, escalating hospital costs, a need to reduce hospital readmission rates, an aging population, and a high rate of people with chronic disease. The largest factor driving this market is the rapidly growing rate of those afflicted with chronic disease.

  • [By Bryan Murphy]

    As much progress as the remote medical monitoring device market has made in recent years, we’ve still only scratched the surface. The surface has been scratched though. The Dexcom G5 mobile glucose monitor from DexCom, Inc. (NASDAQ:DXCM) is one impressive example. Arguably the first and best entry in the race, DexCom has sent a clear message that consumers and caregivers are ready for a functional device that takes care of itself.

    At the other end of the spectrum is a recent round of products that are less clinical in nature, and more broad-usage friendly. Devices like the Apple Inc. (NASDAQ:AAPL) watch and the Fitbit Inc (NYSE:FIT) line of products are both capable of monitoring heart rates and activity. On the other, neither does it all that well… not like one would expect in a clinical setting. Fitbit has run into a headwind of legal and reputational trouble since it’s been verified that its trackers aren’t all that accurate; Apple avoided such trouble largely because few consumers ever viewed its watches as medical-grade hardware.

    The gap between the Dexcom G5 and the Fitbit fitness trackers, however, is where real opportunity lies. See, the entries to date have proven there is a market for mobile medical devices , but have also proven they have to work as well as the equipment one might expect to find in a doctor’s office or in a hospital.

    It’s this subtle nuance that puts a young company called Biotricity Inc. (OTCMKTS:BTCY) in the spotlight, as it has melded mobile monitoring and quality monitoring, and is now in the midst of making sure they’re marketable… not just to consumers, but to insurance companies (which tend to pay a lot more than the average consumer does). Fitbit missed the mark on both fronts.

    Biotricity is working two different but similar pieces of technology. One is called bioflux, for use by caregivers in a clinical setting, and the other is biolife individuals outside of a clinical setting. Neither is o

Hot Performing Stocks To Invest In Right Now: International Paper Company(IP)

Advisors’ Opinion:

  • [By ]

    In the Lightning Round, Cramer was bullish on T-Mobile US (TMUS) , Lennar (LEN) , Toll Brothers (TOL) , Tyson Foods (TSN) , JB Hunt Transport Services (JBHT) and International Paper (IP) .

  • [By WWW.KIPLINGER.COM]

    International Paper Co. (IP) is the largest containerboard maker in the world. And lest you think theres no growth in this old-line industry, IP supplies 50% of Amazon.com, Inc.s (AMZN) need for cardboard boxes.

  • [By ]

    International Paper (IP) : “The stock is down big. I say at these prices it’s a good buy.”

    Alaska Air Group (ALK) : “It used to be the best before the acquisition and now it’s not great and I can’t recommend it anymore.”